Flushing ASsessment Tool (FAST©): Psychometric properties of a new measure assessing flushing symptoms and clinical impact of niacin therapy

Clinical Drug Investigation

Volumn 29, Issue 4, 2009, Pages 215-229

  Kawata, Ariane K ^a   Revicki, Dennis A ^a   Thakkar, Roopal ^b   Jiang, Ping ^b   Krause, Scott ^b   Davidson, Michael H ^c   Punzi, Henry A ^d   Padley, Robert J ^b  

^a UNITED BIOSOURCE CORPORATION   (United States)

^b ABBOTT LABORATORIES   (United States)

^c UNIVERSITY OF CHICAGO   (United States)

^d TEXAS WOMAN'S UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; LOW DENSITY LIPOPROTEIN CHOLESTEROL; NICOTINIC ACID; PLACEBO; TRIACYLGLYCEROL;

ADULT; ARTICLE; BEDTIME DOSAGE; CARDIOVASCULAR RISK; CLINICAL TRIAL; CONSTRUCT VALIDITY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DAILY LIFE ACTIVITY; DIAGNOSTIC TEST; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; DRUG DOSE TITRATION; DRUG EFFECT; DRUG WITHDRAWAL; DYSLIPIDEMIA; EVALUATION; FEMALE; FLUSHING; FLUSHING ASSESSMENT TOOL; HUMAN; ISCHEMIC HEART DISEASE; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PATIENT COMPLIANCE; PATIENT SATISFACTION; PRIORITY JOURNAL; PROSPECTIVE STUDY; PSYCHOMETRY; SIDE EFFECT; SLEEP; TEST RETEST RELIABILITY; TREATMENT DURATION; VALIDITY;

ADULT; AGED; AGED, 80 AND OVER; COMPUTERS, HANDHELD; DELAYED-ACTION PREPARATIONS; DOUBLE-BLIND METHOD; DYSLIPIDEMIAS; FEMALE; FLUSHING; HUMANS; MALE; MEDICAL RECORDS SYSTEMS, COMPUTERIZED; MIDDLE AGED; NIACIN; PATIENT SATISFACTION; PROSPECTIVE STUDIES; PSYCHOMETRICS; QUESTIONNAIRES; SEVERITY OF ILLNESS INDEX; VASODILATOR AGENTS;

EID: 62949162721     PISSN: 11732563     EISSN: None     Source Type: Journal    
DOI: 10.2165/00044011-200929040-00001     Document Type: Article

References (22)

1. Brown BG, Zhao XQ. Nicotinic acid, alone and in combinations, for reduction of cardiovascular risk. Am J Cardiol 2008; 101 (8A): 58B-62B
2. Knopp RH, Ginsberg J, Albers JJ, et al. Contrasting effects of unmodified and time-release forms of niacin on lipoproteins in hyperlipidemic subjects: clues to mechanism of action of niacin. Metab 1985; 34: 642-50
3. Knopp RH, Alagona P, Davidson M, et al. Equivalent efficacy of a time-release form of niacin (Niaspan) given once-a-night versus plain niacin in the management of hyperlipidemia. Metab 1998; 47: 1097-104
4. Hays RD, Morales LS. The RAND-36 measure of health-related quality of life. Ann Med 2001; 33 (5): 350-7
5. Hays RD, Sherbourne CD, Mazel RM. The RAND 36-Item Health Survey 1.0. Health Econ 1993; 2: 217-27
6. Jaeschke R, Singer J, Guyatt GH. Measurement of health status: ascertaining the minimal clinically important difference. Control Clin Trials 1989; 10 (4): 407-15
7. SAS Institute, Inc. SAS software, version 9.1. Cary (NC): SAS Institute, Inc., 2002-2003
8. Deyo RA, Diehr P, Patrick DL. Reproducibility and responsiveness of health status measures: statistics and strategies for evaluation. Control Clin Trials 1991; 12 (4 Suppl.): 142S-58S
9. Hays R, Revicki DA. Reliability and validity (including responsiveness). In: Fayers P, Hays R, editors. Assessing quality of life in clinical trials. 2nd ed. New York (NY): Oxford University Press, 2005: 25-39
10. Guyatt GH, Osoba D, Wu AW, et al. Methods to explain the clinical significance of health status measures. Mayo Clin Proc 2002; 77: 371-83
11. Revicki DA, Hays RD, Cella D, et al. Recommended methods for determining responsiveness and minimally important differences for patient-reported outcomes. J Clin Epidemiol 2008; 61 (2): 102-9
12. Eton DT, Cella D, Bacik J, et al. A brief symptom index for advanced renal cell carcinoma. Health Qual Life Outcomes 2006; 4: 68
13. Norman GR, Sloan JA, Wyrwich KW. Interpretation of changes in health-related quality of life: the remarkable universality of half a standard deviation. Med Care 2003; 41 (5): 582-92
14. Wilson PWF, D'Agostino RB, Levy D, et al. Prediction of coronary heart disease using risk factor categories. Circulation 1998; 97: 1837-47
15. Cohen J. Statistical power analysis for the behavioral sciences. 2nd ed. Hillsdale (NJ): Lawrence Erlbaum Associates, 1988
16. Norquist JM, Watson DJ, Qinfen Y, et al. Validation of a questionnaire to assess niacin-induced cutaneous flushing. Curr Med Res Opin 2007; 23 (7): 1549-60
17. Karas RH, Kashyap ML, Knopp RH, et al. Long term safety and efficacy of a combination of niacin extended release and simvastatin in patients with dyslipidemia: the OCEANS study. Am J Cardiovasc Drugs 2008; 8 (2): 69-81
18. Ballantyne CM, Davidson MH, McKenney J, et al. Comparison of the safety and efficacy of a combination tablet of niacin extended-release and simvastatin vs simvastatin monotherapy in patients with elevated non-HDL cholesterol (from the SEACOAST I study). Am J Cardiol 2008; 101 (10): 1428-36
19. Ballantyne CM, Davidson MH, McKenney J, et al. Comparison of the efficacy and safety of a combination tablet of niacin extended-release and simvastatin with simvastatin 80 mg monotherapy: the SEACOAST II (high-dose) study. J Clin Lipid 2008; 2: 79-90
20. Capuzzi DM, Guyton JR, Morgan JM, et al. Efficacy and safety of an extended-release niacin (Niaspan): a long-term study. Am J Cardiol 1998; 82 (12A): 74U-81U; discussion 85U-6U
21. Revicki DA, Osoba D, Fairclough D, et al. Recommendations on health-related quality of life research to support labeling and promotional claims in the United States. Qual Life Res 2000; 9: 887-900
22. Leidy NK, Revicki DA, Geneste B. Recommendations for evaluating the validity of quality of life claims for labeling and promotion. Value Health 1999; 2: 113-27